Summary by Moomoo AI
Biodexa Pharmaceuticals announced the appointment of PKF Littlejohn LLP as its new independent registered public accounting firm, effective October 31, 2024, following the resignation of Forvis Mazars LLP on October 25, 2024. The change was initiated after Forvis Mazars's notice of intent to resign, followed by a tender process evaluating both commercial terms and expertise of potential candidates.The reports from Forvis Mazars for fiscal years 2022 and 2023 contained no adverse opinions, except for a modification regarding the company's ability to continue as a going concern. During these periods and through October 25, 2024, there were no disagreements on accounting principles, practices, financial statement disclosure, or auditing procedures.The company confirmed that prior to the appointment, there were no consultations with PKF Littlejohn regarding accounting principles, audit opinions, or financial reporting matters. The transition process complies with SEC reporting requirements, with Forvis Mazars providing a letter to the SEC confirming these disclosures.
